🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Mexico / NCT06883409
Recruiting Not applicable

Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer

NCT06883409 · tracked via the Priya Life Science Mexico tracker
Phase
Not applicable
Started
2022-05-19
Last updated
2025-03-26

Condition(s) studied

Ovarian Neoplasms

Investigational drug(s) / intervention(s)

Interval Cytoreduction Surgery

Interval Cytoreduction Surgery: The procedure started with the cytoreduction of highest complexity (determined at the time of initial inspection), after which, if necessary, the patient underwent a complete hysterectomy, bilateral salpingo-oophorectomy, omentectomy, or partial peritonectomy and excision of any peritoneal implants present. The magnitude of the surgical procedures will be classified as: 1. Standard surgery: minimal hysterectomy, adnexectomy y omentectomy 2. Radical Surgery: included resection of the ovaries, of the rectouterine excavation (pouch of Douglas) and or the peritoneum between the bladder and uterus, hysterectomy, rectosigmoid colectomy, and complete omentectomy 3. Supra-radical Surgery: included other procedures such as splenectomy, diaphragm resection, or other intestinal resection.

Study summary

This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage III-IV * Partial and complete response to treatment with QTNA after 3-4 cycles, evaluated by PET-CT imaging study, patients that the functional unit decides to incorporate into the project. * Ca 125 which will have to be less than 200 * ECOG 0 to 2 without medical contraindication to perform surgery (≤ ASA 2 or ≤ Goldman 2). Exclusion Criteria: * Partial response with persistence of ascites or pleural effusion. * With unresectability criteria (multiple intrahepatic liver metastases, retroperitoneal lymph node conglomerates \>2cm above the renal lymph nodes, metastatic disease above the diaphragm, multiple intestinal involvement and mesentery retraction).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Instituto Nacional de Cancerologia México Tlalpan Recruiting

More Instituto Nacional de Cancerologia de Mexico trials in Mexico

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06883409 on ClinicalTrials.gov ↗ ← All trials in Mexico